Refine your search

Content type
Tags
Firm name
Author
Jurisdiction
Language

1,371 results found

Article
Ask Lexy

Sheppard Mullin Richter & Hampton LLP | USA | 23 Jun 2022

FDA Issues Untitled Letter to Althera Pharmaceuticals for Statements Relating to ROSZET®

On June 2, 2022, the US Food and Drug Administration (FDA) Office of Prescription Drug Promotion (OPDP) issued an untitled letter [1] to Althera…
Article
Ask Lexy

McDermott Will & Emery | USA | 23 Jun 2022

Lost and “Found”: Fourth Circuit Interpretation of Discovery in Support of Foreign Litigation Opens Circuit Split

The US Court of Appeals for the Fourth Circuit held that a corporation that is not physically present in a district is not “found” in the district…
Article
Ask Lexy

EIP | European Union, United Kingdom | 7 Jun 2022

Patents Court affirms power to grant injunctions for pre-grant patents, but refuses injunction for Novartis

Swiss drug-maker, Novartis, sought a preliminary injunction to keep Teva and four other generics off the market for its prescription-only relapse…
Article
Ask Lexy

Rouse | China | 2 May 2022

Trade Secret Litigation in China

In this report we focus on trade secret litigation in China. We examine a selection of published trade secret cases in our CIELA database from the…
Article
Ask Lexy

Sheppard Mullin Richter & Hampton LLP | USA | 19 Apr 2022

FDA Issues Untitled Letter to Bausch Health Companies for Misleading Statements Relating to DUOBRII™

On March 31, 2022, the Office of Prescription Drug Promotion (OPDP) of the U.S. Food and Drug Administration (FDA) issued an untitled letter to…
Article
Ask Lexy

NLO | European Union, Netherlands | 15 Apr 2022

Infringement on new-use-patents: reasonably required effective measures

In 2017 an article appeared by Kleemans and Drok about the interpretation of Swiss-type claims and EPC-2000 claims. In this article, they discuss the…
Article
Ask Lexy

McDermott Will & Emery | France | 24 Mar 2022

Médicament générique - action en contrefaçon - Mesures provisoires

CA Paris, 9 novembre 2021, aff. Eli Lilly c. Zentiva France (n°RG 21/01880) La Cour d'appel de Paris confirme l'injonction préliminaire…
Article
Ask Lexy

McDermott Will & Emery | France | 23 Mar 2022

Generic medicine - infringement action - provisional measures

CA Paris, November 9, 2021, Eli Lilly v. Zentiva France (Docket No. 21/01880) The Paris Court of Appeal upheld a preliminary injunction prohibiting…
Article
Ask Lexy

Morrison & Foerster LLP | USA | 9 Mar 2022

FDA’s loud and clear message: Engage with FDA early and formally

On February 10, 2022, the U.S. Food and Drug Administration (FDA) held a public Oncologic Drugs Advisory Committee (ODAC) meeting to discuss the…
Article
Ask Lexy

Covington & Burling LLP | USA | 17 Feb 2022

2021 End-of-Year Summary of FDA Advertising and Promotion Enforcement Activity

This e-alert reviews trends emerging from Warning Letters and untitled letters concerning product advertising and promotion issued in 2021 by the…
Previous page 1 2 3 ...